Paper34699552
Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
Hussain Alsayed HA and 5 others. PLoS One, 2021. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. Papers, record 34699552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34699552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alanine | Major topic |
| Adenosine Monophosphate | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Intensive Care Units | Major topic |
| Antiviral Agents | Major topic |
| COVID-19 | Major topic |
| Respiration, Artificial | Major topic |
| Humans | |
| Male | |
| Female | |
| Retrospective Studies | |
| Middle Aged | |
| Aged | |
| Treatment Outcome | |
| SARS-CoV-2 | |
| Hospitalization |
Source PubMed
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32706859 | Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32706859 | PubMed |
| 2 | 32020029 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. | Cell Res | 2020 | https://conductscience.org/library/papers/32020029 | PubMed |
| 3 | 28659436 | Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/28659436 | PubMed |
| 4 | 32171076 | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. | Lancet | 2020 | https://conductscience.org/library/papers/32171076 | PubMed |
| 5 | 32032529 | Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. | Lancet | 2020 | https://conductscience.org/library/papers/32032529 | PubMed |
| 6 | 32423584 | Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. | Lancet | 2020 | https://conductscience.org/library/papers/32423584 | PubMed |
| 7 | 32240634 | Estimates of the severity of coronavirus disease 2019: a model-based analysis. | Lancet Infect Dis | 2020 | https://conductscience.org/library/papers/32240634 | PubMed |
| 8 | 31924756 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. | Nat Commun | 2020 | https://conductscience.org/library/papers/31924756 | PubMed |
| 9 | 32344679 | The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. | J Clin Med | 2020 | https://conductscience.org/library/papers/32344679 | PubMed |
| 10 | 32445440 | Remdesivir for the Treatment of Covid-19 - Final Report. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32445440 | PubMed |
| 11 | 33631066 | Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33631066 | PubMed |
| 12 | 32516797 | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. | Nature | 2020 | https://conductscience.org/library/papers/32516797 | PubMed |
| 13 | 32678530 | Dexamethasone in Hospitalized Patients with Covid-19. | N Engl J Med | 2021 | https://conductscience.org/library/papers/32678530 | PubMed |
| 14 | 32732352 | Remdesivir for severe covid-19: a clinical practice guideline. | BMJ | 2020 | https://conductscience.org/library/papers/32732352 | PubMed |
| 15 | 33264556 | Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33264556 | PubMed |
| 16 | 32187464 | A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32187464 | PubMed |
| 17 | 32821939 | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. | JAMA | 2020 | https://conductscience.org/library/papers/32821939 | PubMed |
| 18 | 32253226 | An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32253226 | PubMed |
| 19 | 33099706 | Revisited COVID-19 Mortality and Recovery Rates: Are we Missing Recovery Time Period? | J Med Syst | 2020 | https://conductscience.org/library/papers/33099706 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42824417 | Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42824417 | PubMed |
| 42516643 | Practical Application of Remdesivir-Based Regimens in COVID-19: A Retrospective Case-Control Analysis. | Med J Islam Repub Iran | 2026 | https://conductscience.org/library/papers/42516643 | PubMed |
| 41239269 | Severe myocardium suppression in two congenital heart disease patients after remdesivir use - a case report. | BMC Pediatr | 2025 | https://conductscience.org/library/papers/41239269 | PubMed |
| 40709071 | Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. | Health Sci Rep | 2025 | https://conductscience.org/library/papers/40709071 | PubMed |
| 38541734 | Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38541734 | PubMed |
| 38420058 | Retrospective Cohort Study on Determinants of Mechanical Ventilation Duration of COVID-19 ICU Patients. | Cureus | 2024 | https://conductscience.org/library/papers/38420058 | PubMed |
| 38344559 | Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis. | Cureus | 2024 | https://conductscience.org/library/papers/38344559 | PubMed |
| 38339996 | Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. | J Pediatric Infect Dis Soc | 2024 | https://conductscience.org/library/papers/38339996 | PubMed |
| 38144436 | The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions. | Clin Pathol | 2023 | https://conductscience.org/library/papers/38144436 | PubMed |
| 37456740 | Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37456740 | PubMed |
| 37422621 | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study. | BMC Infect Dis | 2023 | https://conductscience.org/library/papers/37422621 | PubMed |
| 37304919 | Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study. | Cardiol Res | 2023 | https://conductscience.org/library/papers/37304919 | PubMed |
| 37243285 | Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. | Viruses | 2023 | https://conductscience.org/library/papers/37243285 | PubMed |
| 37048734 | Mortality, Intensive Care Unit Admission, and Intubation among Hospitalized Patients with COVID-19: A One-Year Retrospective Study in Jordan. | J Clin Med | 2023 | https://conductscience.org/library/papers/37048734 | PubMed |
| 36983370 | Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. | J Clin Med | 2023 | https://conductscience.org/library/papers/36983370 | PubMed |
| 36817340 | Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave. | Vacunas | 2023 | https://conductscience.org/library/papers/36817340 | PubMed |
| 36505104 | Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan. | Cureus | 2022 | https://conductscience.org/library/papers/36505104 | PubMed |
| 36224452 | Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review. | Infection | 2023 | https://conductscience.org/library/papers/36224452 | PubMed |
| 36156891 | Serum ACE2 Level is Associated With Severe SARS-CoV-2 Infection: A Cross-Sectional Observational Study. | Biomark Insights | 2022 | https://conductscience.org/library/papers/36156891 | PubMed |
| 36123499 | A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects. | Naunyn Schmiedebergs Arch Pharmacol | 2023 | https://conductscience.org/library/papers/36123499 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34699552
GET https://conductscience.org/api/papers/v1/34699552/cited_by?page=2